Tram Tran - 25 May 2022 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Director
Signature
/s/ David C. Hastings as attorney-in-fact for Tram Tran
Issuer symbol
ABUS
Transactions as of
25 May 2022
Net transactions value
$0
Form type
4
Filing time
26 May 2022, 16:13:28 UTC
Previous filing
12 Nov 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Award $0 +41,000 $0.000000 41,000 25 May 2022 Common Shares 41,000 $2.25 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 25, 2022, the date of the grant.
F2 The option is fully vested and exercisable as of the date of the grant.